Hillstar Bio has successfully closed a $67 million Series A financing round led by various investors. The funds will be used to advance their lead TRBV9 program and broaden their pipeline in precision immunotherapy.

Hillstar Bio, a biotechnology company, announced the successful closing of a $67 million Series A financing round. The funding was led by a syndicate of investors from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience. The proceeds will fund the advancement of the company's lead TRBV9 program and progress their broader pipeline in autoimmune treatments. Hillstar Bio focuses on a precision-driven approach to target pathogenic immune cells while preserving healthy ones.